- Trials with a EudraCT protocol (63)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
63 result(s) found for: Cyclin D1.
Displaying page 1 of 4.
EudraCT Number: 2018-002231-24 | Sponsor Protocol Number: PROICM2018-01NEX | Start Date*: 2018-08-06 | |||||||||||
Sponsor Name:Institut régional du Cancer de Montpellier | |||||||||||||
Full Title: A randomized phase III trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failure of standard therapies, according... | |||||||||||||
Medical condition: Metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003389-25 | Sponsor Protocol Number: CC-5013-MCL-002 | Start Date*: 2011-04-11 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 2, MULTICENTER, RANDOMIZED OPEN-LABEL STUDY TO DETERMINE THE EFFICACY OF LENALIDOMIDE (REVLIMID®) VERSUS INVESTIGATOR’S CHOICE IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA | |||||||||||||
Medical condition: Patients with mantle cell lymphoma are refractory to their regimen or have relapsed once or up to three times. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) CZ (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) DK (Completed) SE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001965-41 | Sponsor Protocol Number: BRD/06/052 | Start Date*: 2008-09-05 |
Sponsor Name:University College London | ||
Full Title: Phase III, multicentre, randomised study of fludarabine/cyclophosphamide combination with or without Rituximab in patients with untreated mantle cell lymphoma | ||
Medical condition: Mantle Cell Lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-001698-89 | Sponsor Protocol Number: Monet | Start Date*: 2006-06-08 |
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | ||
Full Title: Molecular profiling of postmenopausal women with breast cancer on neoadjuvant exemestane or tamoxifen | ||
Medical condition: Early or locally advanced breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-007756-34 | Sponsor Protocol Number: CC-5013-MCL-001 | Start Date*: 2009-02-06 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 2, multicenter, single-arm, open-label study to determine the efficacy and safety of single-agent lenalidomide (Revlimid ®) in patients with mantle cell NHL who have relapsed or progressed ... | |||||||||||||
Medical condition: Mantle cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) ES (Completed) AT (Completed) HU (Completed) FR (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004628-31 | Sponsor Protocol Number: FIL_V-RBAC | Start Date*: 2018-05-15 | |||||||||||
Sponsor Name:Fondazione Italiana Linfomi ONLUS | |||||||||||||
Full Title: Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL) | |||||||||||||
Medical condition: Mantle Cell Lymphoma in elderly patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005739-23 | Sponsor Protocol Number: FIL-RBAC500 | Start Date*: 2012-03-06 | |||||||||||
Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | |||||||||||||
Full Title: Phase II study of age‐adjusted R‐BAC (Rituximab, Bendamustine, Cytarabine) as induction therapy in older patients with Mantle Cell Lymphoma (MCL) | |||||||||||||
Medical condition: Patients with an established histological diagnosis of MCL on lymph‐node biopsy, bone marrow biopsy, or extranodal tissue. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002374-46 | Sponsor Protocol Number: UC-0110/1807 | Start Date*: 2018-11-09 |
Sponsor Name:UNICANCER | ||
Full Title: A randomised phase II trial assessing REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas. | ||
Medical condition: Patients aged ≥18 years old with metastatic gastro-oesophageal adenocarcinomas after failure of a first-line fluoropyrimidine and platinum-based chemotherapies. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-001521-41 | Sponsor Protocol Number: UoL001304 | Start Date*: 2017-09-18 | |||||||||||
Sponsor Name:University of Liverpool | |||||||||||||
Full Title: A window of opportunity study to assess the biological effects of progesterone in premenopausal ER-positive, PgR-positive early breast cancer | |||||||||||||
Medical condition: Premenopausal ER-positive, PgR-positive early breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006177-32 | Sponsor Protocol Number: CC-5013-MCL-003 | Start Date*: 2010-01-06 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, FIRST LINE MAINTENANCE STUDY OF LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH MANTLE-CELL LYMPHOMA | |||||||||||||
Medical condition: Mantle-Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) FR (Completed) DE (Completed) ES (Completed) PT (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017675-16 | Sponsor Protocol Number: OFT113725 | Start Date*: 2010-11-30 | ||||||||||||||||
Sponsor Name:Plymouth Hospitals NHS Trust | ||||||||||||||||||
Full Title: Phase II Trial of Single Agent Ofatumumab in Relapsed / Refractory Mantle Cell Lymphoma | ||||||||||||||||||
Medical condition: Relapsed or refractory Mantle Cell Lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-005057-36 | Sponsor Protocol Number: GLG-801-07 | Start Date*: 2018-05-17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GLG Pharma S.A. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability and Recommended Phase II Dose (RP2D) of GLG-801 in patients with Advanced Solid Tumors (Phase I); and safety, tolerability and ant... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Metastatic triple-negative breast cancer Breast cancer, prostate cancer, ovarian cancer, head and neck cancer, NSCLC, colorectal cancer, gastric cancer, esophageal cancer, bladder cancer, renal ce... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004056-11 | Sponsor Protocol Number: PCI-32765MCL3002 | Start Date*: 2014-01-30 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects ... | |||||||||||||
Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) BE (Completed) GB (GB - no longer in EU/EEA) DE (Ongoing) HU (Completed) IE (Completed) IT (Ongoing) PT (Prematurely Ended) SK (Completed) ES (Ongoing) NL (Ongoing) FR (Completed) PL (Ongoing) CZ (Ongoing) GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000129-12 | Sponsor Protocol Number: PCYC-1143-CA | Start Date*: 2017-10-10 | |||||||||||
Sponsor Name:Pharmacyclics LLC | |||||||||||||
Full Title: Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma | |||||||||||||
Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Ongoing) BE (Ongoing) HU (Ongoing) ES (Ongoing) NL (Ongoing) GR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015498-11 | Sponsor Protocol Number: 3066K1-4438/B1771007 | Start Date*: 2011-07-29 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc, a wholled owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA | |||||||||||||
Full Title: A Randomized Phase 4 Study Comparing 2 Intravenous Temsirolimus (TEMSR) Regimens in Subjects With Relapsed, Refractory Mantle Cell Lymphoma | |||||||||||||
Medical condition: Relapsed Refractory Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) HU (Completed) DE (Completed) IT (Completed) BG (Prematurely Ended) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012807-25 | Sponsor Protocol Number: IIL-MCL0208 | Start Date*: 2010-01-28 | ||||||||||||||||||||||||||
Sponsor Name:IIL INTERGRUPPO ITALIANO LINFOMI ONLUS | ||||||||||||||||||||||||||||
Full Title: A PHASE III MULTICENTER, RANDOMIZED STUDY WITH LENALIDOMIDE (Revlimid) MAINTENANCE VERSUS OBSERVATION AFTER INTENSIFIED INDUCTION REGIMEN CONTAINING RITUXIMAB FOLLOWED BY HIGH DOSE CHEMOTHERAPY A... | ||||||||||||||||||||||||||||
Medical condition: Mantel cell lymphoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Ongoing) PT (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001040-62 | Sponsor Protocol Number: GBG78/BIG1-13 | Start Date*: 2013-11-14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GBG Forschungs GmbH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor, in patients with hormone-receptor positive, HER2 normal primary breast cancer with high relapse r... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: About one-third of patient with hormone-receptor positive, HER2 negative breast cancer and residual disease after standard of care - including adequate surgery - have a substantial risk of relapse ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) AT (Completed) IE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-022939-11 | Sponsor Protocol Number: PCYC-1104-CA | Start Date*: 2011-05-17 | ||||||||||||||||
Sponsor Name:Pharmacyclics, Incorporated | ||||||||||||||||||
Full Title: Multicenter phase 2 study of Bruton’s tyrosine kinase (Btk) inhibitor, PCI-32765, in relapsed or refractory mantle cell lymphoma | ||||||||||||||||||
Medical condition: Relapsed or refractory mantle cell lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) AT (Completed) | ||||||||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2014-003893-17 | Sponsor Protocol Number: SAKK36/13 | Start Date*: 2017-11-23 | ||||||||||||||||
Sponsor Name:SAKK, Swiss Group for Clinical Cancer Research | ||||||||||||||||||
Full Title: Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial | ||||||||||||||||||
Medical condition: Histologically confirmed mantle cell lymphoma in need of systemic treatment Refractory or relapsed disease after pretreatment of non-bortezomib containing chemotherapy including high-dose therapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004553-72 | Sponsor Protocol Number: J2N-OX-JZNM(LOXO-BTK-20019) | Start Date*: 2021-07-14 | |||||||||||
Sponsor Name:Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321) | |||||||||||||
Medical condition: Mantle cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) FR (Ongoing) AT (Ongoing) CZ (Ongoing) DE (Ongoing) PT (Ongoing) HU (Completed) NL (Ongoing) BE (Ongoing) IT (Ongoing) DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.